Nonapeptide
DSIP Protocol
A blood-brain-barrier-permeable nonapeptide investigated in research for delta-wave EEG modulation, HPA-axis dampening and stress-induced analgesia — a benchmark molecule in sleep architecture and neuroendocrine research.
Nonapeptide Mechanism
Three central nervous system axes routinely studied in DSIP research models.
Central Penetrance
A nine-residue sequence that crosses the blood-brain barrier in research models, enabling direct examination of central sleep, stress and analgesia circuitry following peripheral administration.
Sleep Architecture
Investigated for modulation of slow-wave EEG signatures and delta-band power during non-REM sleep, with classical electrophysiology models forming the bulk of the published literature.
Stress & Analgesia
Studied for attenuation of corticotropin and corticosterone responses under stress challenge, including opioid-withdrawal and stress-induced analgesia paradigms in preclinical models.
Research Applications
Three primary domains in which DSIP is deployed across laboratory investigations.
Slow-Wave Studies
Used in electrophysiological research investigating delta-band power, NREM stage transitions and circadian-phase coupling under controlled light and stress conditions.
HPA-Axis Models
Examined in rodent stress-challenge paradigms for effects on ACTH, corticosterone pulsatility and behavioural correlates of stress-induced analgesia.
Pituitary Signalling
Investigated in pituitary and hypothalamic preparations for effects on somatotropic and thyrotropic axes, and as a reference peptide in opioid-withdrawal research models.
Compound Profile
Identity at a glance.
| Property | Detail |
|---|---|
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) |
| Formula & weight | C35H48N10O15 · 848.8 g/mol · CAS 62568-57-4 |
| Other names | Emideltide; delta sleep-inducing peptide |
| Discovery | Isolated in 1977 from the cerebral venous blood of rabbits in which sleep had been induced by thalamic stimulation |
| Regulatory status | Not an approved medicine anywhere |
Published Research
Four decades of DSIP research.
| Study | What it found |
|---|---|
| 1977 — Characterisation | Schoenenberger and Monnier characterised a nonapeptide that promoted delta-wave (slow-wave) EEG activity when given to recipient animals.1 |
| 1984 — Early review | A review of the first decade of research summarised effects on sleep, stress hormones and pain, but noted inconsistent results between laboratories.2 |
| 1992 — Insomnia trial | A small double-blind study examined DSIP’s effects on sleep in patients with chronic insomnia.3 |
| 2006 — “Unresolved riddle” | A review concluded that, despite decades of work, DSIP’s gene, precursor protein and receptor had still not been identified, leaving its physiological role unclear.4 |
Regulatory & Research Status
Where DSIP stands in 2026.
| Date | Development |
|---|---|
| April 2026 | DSIP was one of twelve peptides removed from the US FDA’s Category 2 compounding list. |
| July 2026 | The FDA’s Pharmacy Compounding Advisory Committee voted 6–7 (one abstention) against adding emideltide (DSIP) to the 503A bulks list for proposed opioid-withdrawal, insomnia and narcolepsy uses — the only peptide reviewed at the meeting not to be recommended. |
Evidence Quality & Limitations
DSIP’s evidence base is old, small and inconsistent. Its endogenous source, gene and receptor remain unidentified, many early findings were not reproduced across laboratories, and controlled clinical data are limited to small studies. Treat it as an exploratory research tool rather than a validated sleep-pathway probe.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74:1282–6. PubMed
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8:83–93. PubMed
- Bes F, et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992;26:193–7. PubMed
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97:303–9. PubMed
Technical FAQ
Questions researchers ask most often.
How does DSIP compare to other sleep-research peptides?
DSIP is distinguished by its short nine-residue sequence, BBB penetrance and direct historical association with delta-band EEG research. Unlike orexin-pathway or melatonergic tools, it acts as a broader neuromodulator studied across sleep, stress and analgesia paradigms rather than a single receptor target.
What is the stability and storage profile?
DSIP is lyophilised for maximum molecular stability. Store the dry vial in a cool, dark environment. Following reconstitution with Bacteriostatic Water, refrigerate and use within the validated stability window for the study protocol.
What dosing protocol is used in research?
Preclinical protocols typically employ short pre-dark-phase administration windows in rodent sleep models, with dose ranges scaled to EEG and HPA endpoints. Strictly for laboratory research use only — not for human consumption.
